Imugene Ltd (ASX:IMU, OTC:IUGNF) CEO Leslie Chong joins Proactive’s Jonathan Jackson in the Proactive studio to discuss how the company has advanced its Phase 1 onCARlytics solid tumour trial to combination arm treatment. The trial, known as OASIS, focuses on adult patients with advanced or metastatic solid tumours, aiming to assess the safety and efficacy of intratumoural (IT) injection and intravenous (IV) infusion, alone or combined with the CD19 targeting drug blinatumomab (Blincyto® by Amgen). The Cohort Review Committee (CRC) has reported no safety issues in the onCARlytics monotherapy lead-in study, prompting the clearance of the first cohort and the initiation of the combination arm. The OASIS trial represents a pioneering approach in solid tumour treatment, combining a CD19-expressing oncolytic virus to prime tumours for attack by CD19-targeting therapeutics. The trial's potential to shift the paradigm in solid tumour treatment is underlined by the promising advancements, with the combination arm set to explore the efficacy of onCARlytics in conjunction with blinatumomab. Imugene's progress in the OASIS trial signals a significant step forward in advancing novel immunotherapies for solid tumour patients.
Imugene progresses onCARlytics solid tumour trial to combination arm
